Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05334732 · ClinicalTrials.gov registry record · NA
Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)
A NA study of Breast Cancer, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- NA
- Development phase
- 250
- Enrollment target
- 3
- Study locations
NCT05334732: Recruiting NA study of Breast Cancer, sponsored by Virginia Commonwealth University.
NCT05334732 is a NA study of Breast Cancer that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 250 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05334732, a NA study of Breast Cancer, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- NA
- Development phase
- 250 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to test an evidence-based intervention designed to increase adherence to systemic therapy in Black women compared to enhanced usual care.
Primary Outcome
Initiation will be measured for all therapies based on the number of participants starting at least one cycle of prescribed therapy
Conditions Studied
Interventions
- BEHAVIORAL SIS TALK Back Intervention
Study Locations (3)
District of Columbia
- Medstar Georgetown University Hospital - Washington D.C.
- MedStar Washington Hospital Center - Washington D.C.
Virginia
- Massey Cancer Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2026-02-28 |
| Phase | NA |
What NCT05334732 shows while recruiting
NCT05334732 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which SIS TALK Back Intervention is the first listed.
NCT05334732 reports a single indexed study location in District of Columbia, Virginia.
Frequently Asked Questions
What is clinical trial NCT05334732 about?
NCT05334732 is a clinical study titled "Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)". The purpose of this study is to test an evidence-based intervention designed to increase adherence to systemic therapy in Black women compared to enhanced usual care.
What is the current status of trial NCT05334732?
This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2021-03-01. Estimated completion is 2026-02-28.
What conditions does trial NCT05334732 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT05334732?
The interventions under investigation include: SIS TALK Back Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT05334732?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05334732 being conducted?
This trial has 3 study locations across District of Columbia, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05334732's enrollment target sits among peer trials
250 323rd of 1224 higher than 895 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI